Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort.

Pedrini S, Gupta VB, Hone E, Doecke J, O'Bryant S, James I, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Martins RN; AIBL Research Group.

Sci Rep. 2017 Oct 25;7(1):14057. doi: 10.1038/s41598-017-14020-9.

2.

Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images.

Guo S, Lai C, Wu C, Cen G; Alzheimer's Disease Neuroimaging Initiative.

Front Aging Neurosci. 2017 May 18;9:146. doi: 10.3389/fnagi.2017.00146. eCollection 2017. Erratum in: Front Aging Neurosci. 2017 Sep 05;9:293.

3.

CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord.

Hilton JB, Mercer SW, Lim NK, Faux NG, Buncic G, Beckman JS, Roberts BR, Donnelly PS, White AR, Crouch PJ.

Sci Rep. 2017 Feb 13;7:42292. doi: 10.1038/srep42292.

4.

Association of Cerebrospinal Fluid Ferritin Level With Preclinical Cognitive Decline in APOE-ε4 Carriers.

Ayton S, Faux NG, Bush AI.

JAMA Neurol. 2017 Jan 1;74(1):122-125. doi: 10.1001/jamaneurol.2016.4406. No abstract available.

PMID:
27893873
5.

Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up.

Burnham SC, Rowe CC, Baker D, Bush AI, Doecke JD, Faux NG, Laws SM, Martins RN, Maruff P, Macaulay SL, Rainey-Smith S, Savage G, Ames D, Masters CL, Wilson W, Villemagne VL.

Neurology. 2016 Sep 13;87(11):1093-101. doi: 10.1212/WNL.0000000000003094. Epub 2016 Aug 17.

PMID:
27534714
6.

Lead and manganese levels in serum and erythrocytes in Alzheimer's disease and mild cognitive impairment: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing.

Hare DJ, Faux NG, Roberts BR, Volitakis I, Martins RN, Bush AI.

Metallomics. 2016 Jun 1;8(6):628-32. doi: 10.1039/c6mt00019c.

PMID:
26962965
7.

Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months.

Thai C, Lim YY, Villemagne VL, Laws SM, Ames D, Ellis KA, Rainey-Smith SR, Martins RN, Masters CL, Rowe CC, Maruff P; Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group.

PLoS One. 2015 Oct 2;10(10):e0139082. doi: 10.1371/journal.pone.0139082. eCollection 2015.

8.

Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk.

Leifert WR, Nguyen T, Rembach A, Martins R, Rainey-Smith S, Masters CL, Ames D, Rowe CC, Macaulay SL, François M, Fenech MF; Australian Imaging, Biomarkers and Lifestyle Study Research Group.

J Alzheimers Dis. 2015;48(2):443-52. doi: 10.3233/JAD-150330.

PMID:
26402008
9.

Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.

Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S; AIBL Research Group.

J Alzheimers Dis. 2015;48(1):175-87. doi: 10.3233/JAD-150247.

PMID:
26401938
10.

Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE.

Ayton S, Faux NG, Bush AI; Alzheimer's Disease Neuroimaging Initiative.

Nat Commun. 2015 May 19;6:6760. doi: 10.1038/ncomms7760.

11.

Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.

Pietrzak RH, Lim YY, Neumeister A, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Restrepo C, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P; Australian Imaging, Biomarkers, and Lifestyle Research Group.

JAMA Psychiatry. 2015 Mar;72(3):284-91. doi: 10.1001/jamapsychiatry.2014.2476.

PMID:
25629787
12.

Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation.

Hare DJ, Doecke JD, Faux NG, Rembach A, Volitakis I, Fowler CJ, Grimm R, Doble PA, Cherny RA, Masters CL, Bush AI, Roberts BR.

ACS Chem Neurosci. 2015 Mar 18;6(3):398-402. doi: 10.1021/cn5003557. Epub 2015 Jan 23.

PMID:
25588002
13.

Peripheral α-defensins 1 and 2 are elevated in Alzheimer's disease.

Watt AD, Perez KA, Ang CS, O'Donnell P, Rembach A, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Faux NG, Masters CL, Villemagne VL, Barnham KJ.

J Alzheimers Dis. 2015;44(4):1131-43. doi: 10.3233/JAD-142286.

PMID:
25408207
14.

Response to comment on Moore et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes care 2013;36:2981-2987.

Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, Ellis KA, Bush AI, Faux NG, Watters DA.

Diabetes Care. 2014 Jun;37(6):e151. doi: 10.2337/dc14-0278. No abstract available.

PMID:
24855179
15.

MR-less surface-based amyloid assessment based on 11C PiB PET.

Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Macaulay SL, Ames D, Masters CL, Ellis KA, Villemagne VL, Rowe CC, Fripp J; AIBL Research Group.

PLoS One. 2014 Jan 10;9(1):e84777. doi: 10.1371/journal.pone.0084777. eCollection 2014.

16.

An anemia of Alzheimer's disease.

Faux NG, Rembach A, Wiley J, Ellis KA, Ames D, Fowler CJ, Martins RN, Pertile KK, Rumble RL, Trounson B, Masters CL; AIBL Research Group, Bush AI.

Mol Psychiatry. 2014 Nov;19(11):1227-34. doi: 10.1038/mp.2013.178. Epub 2014 Jan 14.

PMID:
24419041
17.

Altered transition metal homeostasis in Niemann-Pick disease, type C1.

Hung YH, Faux NG, Killilea DW, Yanjanin N, Firnkes S, Volitakis I, Ganio G, Walterfang M, Hastings C, Porter FD, Ory DS, Bush AI.

Metallomics. 2014 Mar;6(3):542-53. doi: 10.1039/c3mt00308f. Epub 2013 Dec 16.

18.

Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts.

Moore EM, Ames D, Mander AG, Carne RP, Brodaty H, Woodward MC, Boundy K, Ellis KA, Bush AI, Faux NG, Martins RN, Masters CL, Rowe CC, Szoeke C, Watters DA.

J Alzheimers Dis. 2014;39(3):661-8. doi: 10.3233/JAD-131265.

PMID:
24246419
19.

Increased risk of cognitive impairment in patients with diabetes is associated with metformin.

Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, Boundy K, Ellis KA, Bush AI, Faux NG, Martins R, Szoeke C, Rowe C, Watters DA; AIBL Investigators.

Diabetes Care. 2013 Oct;36(10):2981-7. doi: 10.2337/dc13-0229. Epub 2013 Sep 5. Erratum in: Diabetes Care. 2013 Nov;36(11):3850.

20.

A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study.

Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, Bush AI, Doecke JD, Ellis KA, Head R, Jones G, Kiiveri H, Martins RN, Rembach A, Rowe CC, Salvado O, Macaulay SL, Masters CL, Villemagne VL; Alzheimer’s Disease Neuroimaging Initiative; Australian Imaging, Biomarkers and Lifestyle Study Research Group.

Mol Psychiatry. 2014 Apr;19(4):519-26. doi: 10.1038/mp.2013.40. Epub 2013 Apr 30.

PMID:
23628985

Supplemental Content

Loading ...
Support Center